Monoclonal Antibody Treatment Available for Those Who Had COVID-19
In November, the FDA issued an Emergency Use Authorization (EUA) for the drug Bamlanivimab, a monoclonal antibody, to treat high-risk patients who have mild to moderate symptoms of COVID-19. This medication is an infusion, administered through an IV. Early data has showed promising results, and in some patients, has prevented progression to severe symptoms and hospitalization. Criteria to undergo this treatment includes:
- Patients 65 years and older;
- Patients 55 and older, who have hypertension or heart disease; OR
- Patients of any age who have diabetes, immune suppression, or obesity with a BMI greater than 34.
We are working closely with Christ Hospital, UC Health, and TriHealth to ensure our patients, who meet these criteria, are considered and can hopefully receive this treatment. Please call our office to discuss.
For more information on Monoclonal Antibody Treatment, visit the CDC at https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html.